Diego Cadavid

Dr. Cadavid is a Senior Leader and Physician-Scientist with more than 24 years of experience in the biopharmaceutical industry and academic research having worked with small molecules and biologics in both common and rare diseases from first- in-human through registration and post-approval studies. Before joining Verge, Dr. Cadavid spent over 6 years in small cap companies as Chief Medical Officer at X4 Pharmaceuticals and Chief Development Officer at Fulcrum Therapeutics. He reported to the CEOs and worked with their leadership teams on successful financing via Series B, an IPO, and several private investments in public equity. He led the Medical Organizations at both X4 and Fulcrum and successfully advanced several small molecules into the clinic and through all phases of drug development. His extensive drug development experience include numerous IND filings and proof of concept studies and global late-stage clinical trials. He has developed and implemented numerous novel biomarkers and successfully developed registrational endpoints in common and rare diseases. Besides CNS, he also has experience in other therapeutic areas such as immunology, hematology and oncology.

Dr. Cadavid began his career in drug development at Biogen where he was the medical lead for the CNS remyelination and Progressive MS areas. Before Biogen, he spent nearly 9 years at Rutgers-New Jersey Medical School where he was Associate Professor of Neurology and Neuroscience and did NIH funded research on the blood brain barrier and brain injury and repair during infections. During his time at Biogen he was also a research faculty at the Massachusetts General Hospital in Boston.

Dr. Cadavid earned his medical degree from Pontificia Universidad Javeriana in Bogotá, Colombia. He is a Board Certified Neurologist with fellowship training in Neuropathology, Microbiology and Immunology. He continues to be clinically active and is an adjunct faculty member at the University of Massachusetts Medical School. He has published over 120 peer reviewed publications, review papers, and book chapters; his work has been cited more than six thousand times, has an H-impact factor of 40, and is an inventor in 7 patent applications.